dc.contributor.author | Harrington, KJ | |
dc.contributor.author | Cohen, EEW | |
dc.contributor.author | Soulières, D | |
dc.contributor.author | Dinis, J | |
dc.contributor.author | Licitra, L | |
dc.contributor.author | Ahn, M-J | |
dc.contributor.author | Soria, A | |
dc.contributor.author | Machiels, J-P | |
dc.contributor.author | Mach, N | |
dc.contributor.author | Mehra, R | |
dc.contributor.author | Burtness, B | |
dc.contributor.author | Swaby, RF | |
dc.contributor.author | Lin, J | |
dc.contributor.author | Ge, J | |
dc.contributor.author | Lerman, N | |
dc.contributor.author | Tourneau, CL | |
dc.coverage.spatial | England | |
dc.date.accessioned | 2024-01-30T10:37:22Z | |
dc.date.available | 2024-01-30T10:37:22Z | |
dc.date.issued | 2023-12-01 | |
dc.identifier | ARTN 106587 | |
dc.identifier | S1368-8375(23)00283-X | |
dc.identifier.citation | Oral Oncology, 2023, 147 pp. 106587 - | en_US |
dc.identifier.issn | 1368-8375 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/6134 | |
dc.identifier.eissn | 1879-0593 | |
dc.identifier.eissn | 1879-0593 | |
dc.identifier.doi | 10.1016/j.oraloncology.2023.106587 | |
dc.identifier.doi | 10.1016/j.oraloncology.2023.106587 | |
dc.description.abstract | BACKGROUND: In the phase 3 KEYNOTE-040 study, pembrolizumab prolonged OS versus chemotherapy in previously treated recurrent or metastatic (R/M) HNSCC. We present a post hoc subgroup analysis by disease recurrence pattern: recurrent-only, recurrent and metastatic (recurrent-metastatic), and metastatic-only HNSCC. MATERIALS AND METHODS: Patients had HNSCC that progressed during or after platinum-containing treatment for R/M disease or had recurrence or progression within 3-6 months of previous platinum-containing definitive therapy for locally advanced disease. Patients were randomly assigned (1:1) to pembrolizumab 200 mg Q3W or investigator's choice of standards of care (SOC): methotrexate, docetaxel, or cetuximab. Outcomes included OS, PFS, ORR, and DOR. The data cutoff was May 15, 2017. RESULTS: There were 125 patients (pembrolizumab, 53; SOC, 72) in the recurrent-only subgroup, 204 in the recurrent-metastatic subgroup (pembrolizumab, 108; SOC, 96), and 166 in the metastatic-only subgroup (pembrolizumab, 86; SOC, 80). The hazard ratio (95% CI) for death for pembrolizumab versus SOC was 0.83 (0.55-1.25) in the recurrent-only, 0.78 (0.58-1.06) in the recurrent-metastatic, and 0.74 (0.52-1.05) in the metastatic-only subgroups. PFS was similar between treatment arms in all subgroups. ORR was 22.6% for pembrolizumab versus 16.7% for SOC in the recurrent-only, 10.2% versus 6.3% in the recurrent-metastatic, and 15.1% versus 8.8% in the metastatic-only subgroups. DOR was numerically longer with pembrolizumab in all subgroups. CONCLUSION: Pembrolizumab provided numerically longer OS and durable responses in all subgroups compared with SOC, suggesting that patients with previously treated R/M HNSCC benefit from pembrolizumab regardless of recurrence pattern. | |
dc.format | Print-Electronic | |
dc.format.extent | 106587 - | |
dc.language | eng | |
dc.language.iso | eng | en_US |
dc.publisher | ELSEVIER | en_US |
dc.relation.ispartof | Oral Oncology | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | en_US |
dc.subject | Head and neck squamous cell carcinoma | |
dc.subject | Metastatic | |
dc.subject | Pembrolizumab | |
dc.subject | Recurrent | |
dc.subject | Humans | |
dc.subject | Squamous Cell Carcinoma of Head and Neck | |
dc.subject | Cetuximab | |
dc.subject | Docetaxel | |
dc.subject | Methotrexate | |
dc.subject | Platinum | |
dc.subject | Neoplasm Recurrence, Local | |
dc.subject | Head and Neck Neoplasms | |
dc.subject | Antineoplastic Combined Chemotherapy Protocols | |
dc.title | Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence. | en_US |
dc.type | Journal Article | |
dcterms.dateAccepted | 2023-10-06 | |
dc.date.updated | 2024-01-30T10:35:58Z | |
rioxxterms.version | VoR | en_US |
rioxxterms.versionofrecord | 10.1016/j.oraloncology.2023.106587 | en_US |
rioxxterms.licenseref.startdate | 2023-12-01 | |
rioxxterms.type | Journal Article/Review | en_US |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/37925894 | |
pubs.organisational-group | ICR | |
pubs.organisational-group | ICR/Primary Group | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Cancer Biology | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy | |
pubs.organisational-group | ICR/ImmNet | |
pubs.publication-status | Published | |
pubs.publisher-url | http://dx.doi.org/10.1016/j.oraloncology.2023.106587 | |
pubs.volume | 147 | |
icr.researchteam | Targeted Therapy | en_US |
dc.contributor.icrauthor | Harrington, Kevin | |
icr.provenance | Deposited by Mr Arek Surman on 2024-01-30. Deposit type is initial. No. of files: 1. Files: 1-s2.0-S136883752300283X-main.pdf | |